By flow cytometry analysis for hepatic CD44+/CD133+ CSCs, rLECT2 treatment dose-dependently and significantly deprived CD44+/CD133+ subpopulation in hepatoma cells (Fig. 5F). This evidence concerns the gene CD44 and hepatocellular carcinoma.